CLINICAL TRIAL | the abstract

Principal Investigator: Dr. Jennifer Cather

An open-label, multi-center phase II study of continuous oral dosing of RO5185426 in previously treated patients with metastatic melanoma.

RO5185426 (Vemurafenib) is approved for metastatic melanoma.  The study assessed the skin toxicities while patients were taking the drug.  It is common for a patient with one melanoma to suffer from a second melanoma; the study surveyed skin cancer development. It was discovered that there is an increase of nonmelanoma skin cancers attributed to Vemurafenib, and these new lesions begin to appear within 6-8 weeks of starting the medication.  Multidisciplinary approaches to oncologic diseases are usually necessary for the best outcomes.

SOTA Formulation Consideration Based on Data:

Patients who take sun sensitizing medications or medications which impair their ability to repair UV-induced DNA damage would benefit from enhanced photoprotection. 

Learn more about the benefits of patent-pending SOTA Shade formula.

Study dates: 2001